Elevance Health, Inc. (ELV)
(Delayed Data from NYSE)
$417.86 USD
+3.85 (0.93%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $417.84 -0.02 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$417.86 USD
+3.85 (0.93%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $417.84 -0.02 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
B Value B Growth C Momentum B VGM
Zacks News
Zimmer Biomet (ZBH) Q2 Earnings Match Estimates, View Raised
by Zacks Equity Research
Barring S.E.T., Zimmer Biomet (ZBH) records strong growth across each of its business segments in the second quarter.
Avantor (AVTR) Q2 Earnings Lag Estimates, FY23 View Revised
by Zacks Equity Research
Despite Avantor's (AVTR) strength in end markets, it reports an overall soft second-quarter performance.
Ensign Group (ENSG) Beats on Q2 Earnings, Raises '23 EPS View
by Zacks Equity Research
Ensign Group's (ENSG) second-quarter results benefit from improved occupancies, skilled and managed care revenue. Rising expenses acted as a partial offset.
Integer Holdings (ITGR) Q2 Earnings Top Estimates, FY23 View Up
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust Medical and Non-Medical Sales, besides strength in all the product lines.
Centene (CNC) Q2 Earnings Beat Estimates on Membership Growth
by Zacks Equity Research
Centene's (CNC) Q2 results benefit from growing premium and service revenues coupled with improving membership.
Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Dip
by Zacks Equity Research
Strength in Hugh Acuity Care segment and Hospice division drive Amedisys (AMED) Q2 performance.
Integra's (IART) Q2 Earnings Top Estimates, 2023 View Cut
by Zacks Equity Research
In CSS, Integra (IART) registers strong growth owing to high single-digit growth in Advanced Energy and mid-single-digit growth in CSF management during Q2.
DexCom (DXCM) Q2 Earnings Beat Estimates, Volumes Remain Strong
by Zacks Equity Research
DexCom's (DXCM) second-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Neogen (NEOG) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Neogen (NEOG) Q4 fiscal 2023 results reflect core growth in both operating segments despite softening market conditions.
LabCorp (LH) Q2 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
A rise in organic revenues, acquisitions, net of divestitures and foreign currency translation drive LabCorp's (LH) Q2 revenues.
HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2023 EPS View
by Zacks Equity Research
HCA Healthcare's (HCA) Q2 results benefit from improving patient volumes and surgeries. However, rising expenses acted as a partial offset.
Edwards Lifesciences (EW) Q2 Earnings Top Estimates, View Up
by Zacks Equity Research
The growing adoption of the PASCAL Precision system in Europe and the United States and Edwards' premium products across all regions have driven Edwards Lifesciences' (EW) Q2 revenues.
Boston Scientific (BSX) Q2 Earnings Beat, Margins Improve
by Zacks Equity Research
Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the second quarter.
CONMED (CNMD) Beats on Q2 Earnings, Ups '23 EPS View
by Zacks Equity Research
CONMED's (CNMD) adjusted second-quarter earnings and sales recover from the disruption in the last two quarters due to implementation of a new warehouse management system.
Baxter (BAX) Beats on Q2 Earnings, Revises 2023 EPS Guidance
by Zacks Equity Research
Baxter's (BAX) second-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.
West Pharmaceutical (WST) Q2 Earnings Beat, HVP Drives Sales
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results reflect a sustained recovery in non-COVID-19 demand amid dismal overall performance.
Chemed (CHE) Q2 Earnings Miss Estimates, '23 EPS View Down
by Zacks Equity Research
Chemed's (CHE) second-quarter 2023 performance reflects strength in the VITAS segment, while expenses weigh on margins.
Align Technology (ALGN) Q2 Earnings Beat, Gross Margin Up
by Zacks Equity Research
Align Technology (ALGN) delivers impressive earnings in the second quarter of 2023.
Teladoc Health (TDOC) Q2 Earnings Top Estimates on Lower Expenses
by Zacks Equity Research
Teladoc Health's (TDOC) Q2 results reflect improving access fees and other revenues coupled with lower expenses.
Merit Medical (MMSI) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the second quarter.
Universal Health (UHS) Q2 Earnings Beat, Boosts '23 EPS View
by Zacks Equity Research
Universal Health's (UHS) Q2 results indicate improved patient admissions and solid segmental performance. Management currently expects adjusted EPS within $9.85-$10.50 for 2023.
Thermo Fisher (TMO) Q2 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Challenging macroeconomic conditions and slowdown in activities in China impede Thermo Fisher's (TMO) Q2 revenues.
Quest Diagnostics (DGX) Q2 Earnings Beat Estimates, FY View Up
by Zacks Equity Research
Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the second quarter of 2023.
NextGen (NXGN) Q1 Earnings Top Estimates, Revenues Surge Y/Y
by Zacks Equity Research
NextGen's (NXGN) first-quarter fiscal 2024 results reflect strength in its revenue sources.
ELV or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. DOCS: Which Stock Is the Better Value Option?